Génome Québec is proud to take part in this initiative of the Terry Fox Research Institute, which will generate new advances in precision medicine.
Research done by the participating institutions will seek to improve treatments for 18,000 cancer patients treated annually in Québec, particularly with the development of immunotherapy.
“Génome Québec salutes this initiative that aims to bring together cancer research organizations and experts, and Montréal’s health institutions. We are proud to participate, as a partner, in supporting genome studies in the projects involved. The Montreal Cancer Consortium promotes clinical integration of genomic data and the implementation of precision medicine. We are convinced that the MCC will help make Montréal a competitive, ideal and sustainable environment for cancer research, for the greater good of patients,” says Daniel Coderre, president and CEO of Génome Québec.